Table 1.
Patient Demographic Data
| Characteristic | Group | No. of Patients |
|---|---|---|
| Demographic characteristics | ||
| Age, y | < 50 | 2 |
| 50-59 | 3 | |
| 60-69 | 3 | |
| 70-79 | 1 | |
| Sex | Male | 6 |
| Female | 3 | |
| BMI, kg/m2 | 25-29.9 | 3 |
| 30-39.9 | 5 | |
| ≥ 40 | 1 | |
| Comorbidities 4C score44 | 0 | 4 |
| 1 | 4 | |
| 3 | 1 | |
| Tobacco use history | No tobacco use | 4 |
| Former tobacco use | 5 | |
| Clinical characteristics on admission | ||
| Admission SF ratio | < 200 | 0 |
| 200-299 | 3 | |
| 300-399 | 3 | |
| ≥ 400 | 3 | |
| Clinical characteristics during admission | ||
| Maximum oxygen requirement during hospital stay | < 28% | 1 |
| 28%-35% | 4 | |
| 40% | 2 | |
| > 60% | 2 | |
| CPAP | 1 | |
| ISARIC 4C score44 | 1-4 | 3 |
| 5-8 | 5 | |
| > 8 | 1 | |
| Length of stay, d | 1-5 | 4 |
| 6-9 | 4 | |
| > 10 | 1 | |
| Maximum National Early Warning Score 2 score45 | 5-6 | 4 |
| ≥ 7 | 5 | |
| Medication during stay | Oral antibiotics | 1 |
| IV antibiotics | 2 | |
| Dexamethasone | 9 | |
| Remdesivir (Gilead Sciences) | 5 | |
| Immunomodulation therapy | 3 | |
| Convalescent plasma | 2 | |
| Colchicine | 2 | |
| Aspirin | 3 | |
| Included in an interventional study? | 7 | |
| Lowest SF ratio during stay | < 200 | 2 |
| 200-299 | 3 | |
| 300-399 | 4 | |
| ≥ 400 | 0 | |
| Maximum Fio2 during stay | < 28% | 1 |
| 28%-35% | 4 | |
| 40% | 2 | |
| > 60% | 2 | |
| CPAP | 1 | |
| Clinical characteristics postdischarge | ||
| MRC Dyspnoea Scale (1-5), 6 wk | 1 | 6 |
| 2 | 2 | |
| Not available | 1 | |
| MRC Dyspnoea Scale (1-5), 3 mo | 1 | 7 |
| 2 | 1 | |
| 3 | 1 | |
| Not available | 0 | |
| Readmittance | Yes | 1 for general surgery unrelated to COVID-19 |
| No | 8 | |
Individuals who formerly used tobacco use all reported ≤ 15 pack y. The pulse oximetry saturation/Fio2 ratio (SF ratio) was calculated by using estimated Fio2 based on flow rate when delivered by nasal cannulae. ISARIC = International Severe Acute Respiratory and Emerging Infection Consortium; MRC = Medical Research Council; pulse oximetry saturation/Fio2 (SF).